ANTHROPIC PAYS $400 MILLION FOR A STARTUP WITH 10 EMPLOYEES AND NO REVENUE — THE COMPANY MAKES DRUGS WITH AI Anthropic has acquired Coefficient Bio, a stealth-stage biotech AI startup that operated for less than a year, employed fewer than 10 people, had no public product, and had generated no known revenue. The all-stock deal was valued at just over $400 million. Against Anthropic’s $965 billion valuation, that represents roughly one-tenth of one percent dilution. The company did not blink. What Anthropic paid for is the team. Coefficient Bio’s founders, Samuel Stanton and Nathan Frey, previously built biological foundation models and machine learning tools for biomolecule design at Genentech. They left to build something more ambitious in stealth. Anthropic found them before anyone else could. The acquisition drops Coefficient Bio’s team directly into Anthropic’s healthcare and life sciences division. The move builds on an earlier product called Claude for Life Sciences and signals that Anthropic is now serious about owning territory in AI drug discovery, a field that has seen billions in investment in the last 18 months. The timing is not accidental. Eli Lilly just paid $2.75 billion for rights to AI-developed drug candidates from Insilico Medicine. Google’s Isomorphic Labs is worth billions on the promise of AI-designed molecules. Anthropic is not content to sell tools to the pharmaceutical industry. It wants a seat at the discovery table. Keywords: Anthropic Coefficient Bio, AI drug discovery, biotech AI acquisition, Claude life sciences, AI pharma